Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (U.S. FDA) Tacrolimus Ointment, 0.03%, the generic version of Protopic1 Ointment, 0.03%, of Leo Pharma AS.

Glenmark's Tacrolimus Ointment, 0.03%, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. According to IQVIATM sales data for the 12‐month period ending June 2023, the Protopic® Ointment, 0.03% market2 achieved annual sales of approximately $15.4 million